You just read:

DARZALEX® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible

News provided by

Janssen Biotech, Inc.

Dec 12, 2017, 06:45 EST